Jiangsu Aidea Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 688488.SS

Jiangsu Aidea Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2023: USD 26.87 M

Jiangsu Aidea Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities is USD 26.87 M for the year ending December 31, 2023, a -5.41% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.

Jiangsu Aidea Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2022 was USD 28.41 M, a 887.44% change year over year.
Jiangsu Aidea Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2021 was USD -3.61 M, a -103.76% change year over year.
Jiangsu Aidea Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2020 was USD 96.01 M, a 2,751.35% change year over year.
Jiangsu Aidea Pharmaceutical Co., Ltd. Net Cash Used Provided By Financing Activities for the year ending December 31, 2019 was USD 3.37 M, a -38.74% change year over year.

Key data

Date	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure	Effect Of Forex Changes On Cash

Shanghai Stock Exchange: 688488.SS

Jiangsu Aidea Pharmaceutical Co., Ltd.

CEO	Mr. Jie Zhang
IPO Date	July 20, 2020
Location	China
Headquarters	No. 2 Liuzhuang Road
Employees	476
Sector	Healthcare
Industries Pharmaceuticals Cleaning Supplies Cosmetics Drugstores & Retail Pharmacies Eyewear Fertilizers Personal Care Plastics

Description

Jiangsu Aidea Pharmaceutical Co., Ltd. develops, produces, and sells pharmaceutical products. It offers folium sennae granules, powdered bacillus tablets, clindamycin hydrochloride capsules, sodium bicarbonate tablets, nitrendipine tablets, metronidazole tablets, compound gentamycin sulfate and procaine hydrochloride sulfate granules, and cefradine capsules, as well as raw materials. The company was founded in 2009 and is based in Yangzhou, China.

Key trends

Past 5 years